Evidence map›Paper›PMID 38201269›Full record

ReviewCells2023

GLP1 Receptor Agonists-Effects beyond Obesity and Diabetes.

Sydney S Wilbon, Mikhail G Kolonin

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 3 pooled it
14.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sydney S WilbonThe Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX 77030, USA.
Mikhail G KoloninThe Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX 77030, USA.ORCID 0000-0002-3743-7869
Brown Foundation · US

Funding

Metabolic consequences of adipocyte progenitor replicative senescence: mechanism and interventionR01DK125922 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KOLONIN, MIKHAIL G, MAHAN, KRISTIN ECKEL · 2021 to 2024
$1.5M
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic ResponseR21DK122234 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GUTIERREZ, ABSALON DENNIS · 2019 to 2021
$582k
NIDDK NIH HHS R01 DK125922NIDDK NIH HHS R21 DK122234
6 · The paper itself

Abstract

Glucagon-like peptide-1 receptor agonists (GLP1RA) have been transformative for patients and clinicians in treating type-2 diabetes and obesity. Drugs of this class, the bioavailability of which is continuously improving, enable weight loss and control blood glucose with minimal unwanted side effects. Since adopting GLP1RA for treating metabolic diseases, animal and clinical studies have revealed their beneficial effects on several other pathologies, including cardiovascular diseases, neurodegeneration, kidney disease, and cancer. A notable commonality between these diseases is their association with older age. Clinical trials and preclinical data suggest that GLP1RA may improve outcomes in these aging-related diseases. Some of the benefits of GLP1RA may be indirect due to their effects on obesity and glucose metabolism. However, there is building evidence that GLP1RA may also act directly on multiple organs implicated in aging-related pathology. This review aims to compile the studies reporting the effects of GLP1RA on aging-related diseases and discuss potential underlying mechanisms.

Indexed as

Diabetes Mellitus, Type 2AgingAnimalsBiological AvailabilityBlood GlucoseHumansObesityBlood Glucoseagingcancercardiovascular diseasediabetesGLP-1 receptor agonistincretinneurodegenerative diseaseobesity

Identifiers

PMID38201269
PMCPMC10778154
OpenAlexW4390347402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.